Skip to content

Individual risk factors crucial in determining a patient's risk of heart attack if taking abacavir

Treatment with tenofovir associated with more bone loss than abacavir, but long-term consequences unclear

Switch to nevirapine can happen at any CD4 count, says European drug regulator

HIV/HCV co-infected women more likely to stop HCV therapy

Truvada/Kaletra HIV PEP combination is safe and effective with a low rate of discontinuations

Nevirapine toxicity in women predicted by liver function, not CD4 count, developing country study reports

Children with HIV are at risk for metabolic problems and heart muscle dysfunction

Inflammation associated with increased mortality risk for patients with HIV, even when CD4 cell count high

Will a long life be a good one?